Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up - Still a Buy?

Key Points

• Aurinia Pharmaceuticals' shares opened up at $11.61, up from a previous closing price of $11.06, with a last traded price of $11.20 and a trading volume of 244,109 shares.
• Analysts maintain a "Buy" rating for Aurinia Pharmaceuticals, with a target price range of $9.00 to $17.00, resulting in an average target of $13.00.
• The company's quarterly earnings report showed a net revenue of $70.01 million, surpassing estimates and a return on equity of 20.06%, despite missing earnings per share expectations.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP shares gapped up prior to trading on Tuesday . The stock had previously closed at $11.06, but opened at $11.61. Aurinia Pharmaceuticals shares last traded at $11.20, with a volume of 244,109 shares trading hands.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AUPH. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Royal Bank Of Canada upped their price objective on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $13.00.

Aurinia Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The company has a 50-day simple moving average of $11.66 and a two-hundred day simple moving average of $9.34. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 25.97 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Kevin Tang purchased 200,000 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were bought at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the purchase, the director owned 11,329,500 shares of the company's stock, valued at $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased a total of 1,300,000 shares of company stock valued at $13,590,000 in the last quarter. 12.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $39,000. USA Financial Formulas acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $50,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $60,000. Finally, Xponance Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $82,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.